Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study

In 2014/2015, tyrosine kinase inhibitors (TKIs) were introduced as a secondary treatment for refractory differentiated thyroid cancer (DTC) in Japan. While renal dysfunction is an adverse event of TKI, data on this adverse event in TKI-treated DTC remains insufficient. Here, we investigated renal fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasaki, Hiroyuki, Yamazaki, Haruhiko, Takasaki, Hirotaka, Suganuma, Nobuyasu, Sakai, Rika, Nakayama, Hirotaka, Toda, Soji, Masudo, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
3700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824644/
https://www.ncbi.nlm.nih.gov/pubmed/31626129
http://dx.doi.org/10.1097/MD.0000000000017588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824644/
https://www.ncbi.nlm.nih.gov/pubmed/31626129
http://dx.doi.org/10.1097/MD.0000000000017588

Ejemplares similares